XML 54 R40.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration Agreements - Ipsen Collaboration (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 23 Months Ended
--- | --- | --- | --- | --- | ---
Feb. 29, 2016 | Sep. 28, 2018 | Mar. 30, 2018 | Sep. 29, 2017 | Sep. 28, 2018 | Sep. 29, 2017 | Dec. 28, 2018 | Dec. 29, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Revenues |  | $ 225,397,000 |  | $ 152,510,000 | $ 625,224,000 | $ 332,405,000 |  |
Licenses |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Revenues |  | 51,323,000 |  | 54,335,000 | 152,261,000 | 74,706,000 |  |
Collaborative Arrangement with Ipsen |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Upfront payment(s) | $ 210,000,000 |  |  |  |  |  |  |
Milestone payments earned |  |  |  |  |  |  |  | $ 125,000,000
Additional milestone achievement | 194,000,000 |  |  |  |  |  |  |
Contingent cash receipts (up to) | 520,300,000 |  |  |  |  |  |  |
Revenues |  | 57,186,000 |  | $ 50,679,000 | $ 145,038,000 | $ 60,703,000 |  |
Research and development arrangement performed for others, reimbursement for costs incurred, percent |  |  |  |  | 35.00% |  |  |
Collaboration period to achieve specified levels of commercial performance |  |  |  |  | 10 years |  |  |
Remaining performance obligation |  | 53,400,000 |  |  | $ 53,400,000 |  |  |
Net contract asset |  | 24,500,000 |  |  | $ 24,500,000 |  |  |
Collaborative Arrangement with Ipsen | GlaxoSmithKline |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  | 3.00% |  |  |
Collaborative Arrangement with Ipsen | Initial and Second |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Royalty tier |  |  |  |  | $ 150,000,000 |  |  |
Collaborative Arrangement with Ipsen | Initial and Second | Minimum |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  | 22.00% |  |  |
Collaborative Arrangement with Ipsen | Initial and Second | Maximum |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  | 26.00% |  |  |
Collaborative Arrangement with Ipsen | Initial |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  | 2.00% |  |  |
Collaborative Arrangement with Ipsen | Second |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percent of royalty on net sale |  |  |  |  | 12.00% |  |  |
Collaborative Arrangement with Ipsen | EMA Approval - RCC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Additional milestone achievement |  | 50,000,000 |  |  | $ 50,000,000 |  |  |
Revenues |  | 36,900,000 |  |  | 36,900,000 |  |  |
Collaborative Arrangement with Ipsen | Health Canada Approval |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Net sales achievement level |  |  |  |  | 5,000,000 |  |  |
Collaborative Arrangement with Ipsen | Net Sales Achievements |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Milestone payments earned |  |  |  |  | 25,000,000 |  |  |
Net sales achievement level |  |  |  |  | 100,000,000 |  |  |
Collaborative Arrangement with Ipsen | HCC Acceptance |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Additional milestone achievement | $ 40,000,000 |  |  |  |  |  |  |
Collaborative Arrangement with Ipsen | Licenses | EMA Approval - RCC |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Revenues |  | $ 200,000 | $ 45,800,000 |  |  |  |  |
Collaborative Arrangement with Ipsen | Licenses | EMA Approval - RCC | Forecast |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  | $ 40,000,000 |
Collaborative Arrangement with Ipsen | Licenses | EMA Approval |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Revenues |  |  |  |  | $ 46,200,000 |  |  |

X
- Definition Collaborative Arrangement, Achievement Levels of Commercial Performance, Period + References No definition available. + Details
Name: | exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
Namespace Prefix: | exel_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement + References No definition available. + Details
Name: | exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount eligible for commercial milestones under collaborations agreement. + References No definition available. + Details
Name: | exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payments Earned + References No definition available. + Details
Name: | exel_MilestonePaymentsEarned
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments, Minimum Net Sales Achievement Amount + References No definition available. + Details
Name: | exel_MilestonePaymentsMinimumNetSalesAchievementAmount
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percent of royalty on net sale. + References No definition available. + Details
Name: | exel_PercentOfRoyaltyOnNetSale
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent + References No definition available. + Details
Name: | exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
Namespace Prefix: | exel_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty Tier + References No definition available. + Details
Name: | exel_RoyaltyTier
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront Payment(s) + References No definition available. + Details
Name: | exel_UpfrontPayments
Namespace Prefix: | exel_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_FinalTierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_InitialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_RoyaltytierAxis=exel_SecondMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_MilestoneObjectiveAxis=exel_EMAApproval1LRCCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_MilestoneObjectiveAxis=exel_HealthCanadaApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_MilestoneObjectiveAxis=exel_RevenueAchievementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_MilestoneObjectiveAxis=exel_EMAApprovalHCCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | exel_MilestoneObjectiveAxis=exel_EMAApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |